financetom
Business
financetom
/
Business
/
JinkoSolar's Q1 Miss Offset By Strong Outlook, Shares Rally As Shipments Surge
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
JinkoSolar's Q1 Miss Offset By Strong Outlook, Shares Rally As Shipments Surge
Apr 29, 2024 6:58 AM

JinkoSolar Holding Co Ltd ( JKS ) shares are trading higher after the Shanghai, China-based company reported first-quarter fiscal 2024 results.

JKS's Q1 revenue decreased 1.2% year-over-year to $3.19 billion, missing the consensus of $3.25 billion.

Quarterly shipments increased 51.2% Y/Y to 21,907 MW (19,993 MW for solar modules and 1,914 MW for cells and wafers).

See Also: Solar Energy Broke Records In 2023, Why Are Shares Tumbling?

Gross margin for the quarter stood at 11.9%, compared to 17.3% in Q1 2023, reflecting decreases in the average selling price of solar modules.

Loss from operations was RMB339.6 million ($47.0 million), compared to RMB1.21 billion income from operations in the first quarter of 2023. 

JinkoSolar Adjusted net income was RMB 470.3 million ($65.1 million), compared to RMB 836.4 million a year ago. Earnings per ADS was RMB 11.28 ($1.56) basic and RMB 5.36 ($0.74) diluted.

As of March 31, JinkoSolar ( JKS ) held $2.44 billion in cash, equivalents, and inventories were $2.79 billion.

Leveraging N-type technology, a broad operation network, and advanced capacity, module shipments grew 53.3% year-over-year to 19.99 GW.

N-type modules comprised nearly 80% of these shipments, with about 50% going to North America. Order book visibility for 2024 currently exceeds 70%. 

The company stated that the newly added installations in China reached 45.7 GW (+35.9% Y/Y). Module exports totaled 61.7 GW (+20% Y/Y). 

JKS is optimistic about increasing global demand for N-type technology and plans to maintain leadership by improving technology, production capabilities, and cost efficiency. By the end of 2024, they aim for N-type cell efficiency at 26.5% and expect these modules to constitute nearly 90% of their shipments due to high demand. 

The company is limiting capacity expansion in 2024, focusing on advanced N-type capacity, including 28 GW at their Shanxi, China plant. 

Outlook: The Shanghai, China-based company expects its second-quarter module shipments to be around 24.0 GW and 26.0 GW.

The company expects FY24 module shipments of 100.0 GW to 110.0 GW. JinkoSolar ( JKS ) expects its annual production capacity for mono wafers, solar cells, and solar modules to reach 120.0 GW, 110.0 GW, and 130.0 GW by the end of 2024.

Price Action: JKS shares are trading higher by 3.56% at $25.00 premarket at the last check Monday.

Now Read: Goldman Sachs Still Likes Solar Stocks Despite SunPower Collapse Fears – Upgrades ENPH, CSIQ

Image: Unsplash

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
United jet suffered navigation parts failure before injury incident
United jet suffered navigation parts failure before injury incident
Mar 18, 2025
WASHINGTON (Reuters) - A United Airlines Boeing 787 jetliner on a January 24 flight bound for Washington from Lagos suffered a failure of two key parts for navigation before a sudden unexpected aircraft movement led to passenger injuries, investigators said. The National Transportation Safety Board said the left and then right inertial reference units failed, which was followed by the...
Sarepta Therapeutics Says Patient Dies After Elevidys Gene Therapy for Duchenne Muscular Dystrophy; Shares Fall
Sarepta Therapeutics Says Patient Dies After Elevidys Gene Therapy for Duchenne Muscular Dystrophy; Shares Fall
Mar 18, 2025
02:37 PM EDT, 03/18/2025 (MT Newswires) -- Sarepta Therapeutics ( SRPT ) shares were down nearly 23% in recent Tuesday trading after the biopharmaceutical company said a young patient with Duchenne muscular dystrophy passed away due to acute liver failure following treatment with its Elevidys gene therapy. Acute liver injury, including failure, is a known side effect of Elevidys and...
IonQ Unusual Options Activity
IonQ Unusual Options Activity
Mar 18, 2025
Deep-pocketed investors have adopted a bearish approach towards IonQ ( IONQ ) , and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in IONQ ( IONQ ) usually suggests something big is about to happen. We gleaned...
'Matrix' co-producer Village Roadshow 'open to all bids' after bankruptcy
'Matrix' co-producer Village Roadshow 'open to all bids' after bankruptcy
Mar 18, 2025
NEW YORK (Reuters) - U.S. film producer Village Roadshow Entertainment Group is open to all bids for a film library that includes rights to well-known movies like The Matrix, Ocean's Eleven, and The Joker, a company attorney said on Tuesday at a court hearing a day after filing for bankruptcy. Los Angeles-based Village Roadshow filed for Chapter 11 with a...
Copyright 2023-2026 - www.financetom.com All Rights Reserved